Morgan Stanley on Compass Pathways (CMPS): 'we view today’s update as incrementally encouraging'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
TD Cowen on Compass Pathways (CMPS) FDA Grant: 'meaningful positive and expected in light of last Saturday’s Executive Order'
April 24, 2026 3:41 PM EDTTD Cowen analyst Ritu Baral reiterated a Buy rating and $29.00 price target on Compass Pathways (NASDAQ: CMPS)
The analyst comments "Our View: We view the CPNV as a meaningful positive and expected in light of last Saturdays Executive Order accelerating development and access for psychedelicbased... More
Oppenheimer on Compass Pathways (CMPS) FDA Grant: 'reinforcing our conviction considering the earlier launch timeline for COMP360 in TRD'
April 24, 2026 1:24 PM EDTOppenheimer analyst Francois Brisebois reiterated an Outperform rating and $20.00 price target on Compass Pathways (NASDAQ: CMPS).
The analyst comments "We view FDA granting a CNPV with agreement on NDA rolling review as reinforcing our conviction considering the earlier launch timeline for COMP360 (psilocybin)... More
Compass Pathways receives FDA rolling review for psychedelic depression drug
April 24, 2026 10:37 AM EDTCompass Pathways plc (NASDAQ: CMPS) announced the U.S. Food and Drug Administration granted the company a rolling New Drug Application review for COMP360, its synthetic psilocybin treatment for treatment-resistant depression.
The FDA also selected COMP360 for the Commissioner's National Priority Voucher program. Companies in this program receive enhanced communications with the agency and a shortened... More
FDA advances psychedelic drug studies for mental health treatment
April 24, 2026 9:10 AM EDTThe Food and Drug Administration announced regulatory actions to support development of psychedelic medications for mental health conditions, following an executive order directing accelerated access to treatments for serious mental illness.
The agency issued national priority vouchers to three companies studying psilocybin for treatment-resistant depression and major depressive disorder, and methylone for post-traumatic stress disorder.
The FDA also approved an early phase clinical study of noribogaine... More
B.Riley Starts Compass Pathways (CMPS) at Buy
April 24, 2026 3:49 AM EDTB.Riley analyst Madison El-Saadi initiates coverage on Compass Pathways (NASDAQ: CMPS) with a Buy rating and a price target of $17.00.
The analyst comments "We are initiating coverage of Compass Pathways plc (CMPS) at Buy with a $17 PT heading into its second Ph3 durability readout (3Q26E) and rolling NDA submission (4Q26E). CMPS is on track to develop the first FDA-approved oral... More
